Dallas, Texas · May 12, 2026
Innovate · Prove · Realize

A purpose-built commercial organization for surgeon-developed medical device IP. From patent to operating room to strategic exit — without the surgeon ever having to become a business operator.

13
Patents in portfolio
1B+
Patient records on platform
15 yr
Field operator track record
§ I
The Mission

The proof of concept
already exists in this industry.

Some surgeon-inventors get to see their IP realize its full commercial value. Others never find out what their invention was actually worth. The difference is never the quality of the invention. The difference is whether a commercial path exists to carry it.

Proof of What's Possible

The orthopedic surgeon who designed the most successful rotator cuff anchor in the world earned $300 million in royalties over the life of the product. One piece of IP. A commercial path that worked. Generational value, realized.

$300M
Royalties to the surgeon-inventor over the product's lifetime
Decades
Of compounding value from a single properly commercialized invention

Two categories of surgeon-inventors exist in this industry. The ones whose IP has a commercial path. And the ones whose IP doesn't. The first category gets to see what their invention is actually worth. The second never finds out.

The difference is never the invention. The difference is infrastructure — the team that runs the commercial layer, the data that proves the market, the manufacturing that supplies it, the distribution that places it, the leverage that closes the deal. Everything that turns a great piece of IP into a real commercial outcome.

LoxaNova is that path. A self-contained commercial engine, built specifically for surgeon IP, run by operators who have built these systems before — so the next surgeon with a great invention has a clear route to the same kind of outcome.
§ II
The Problem We Solve

Surgeons innovate.
The system fails them.

"The surgeon entrepreneur has the idea, the IP, and the clinical proof. What they lack is the time, the commercial infrastructure, and the right team to turn that into lasting value."
  • Large OEMs lowball acquisition offers because the surgeon has no commercial leverage and no utilization data to negotiate with.
  • The proving phase — getting the product into real cases with real surgeons — requires a commercial organization most inventors don't have.
  • 510(k) pathways, manufacturing sourcing, and distribution networks are full-time jobs that surgeons cannot run in parallel with a clinical practice.
  • Without a proven revenue track record, IP sells for a fraction of its actual market value.
  • The window to act is narrow. Maintenance deadlines, competitive products, and market timing don't wait.
§ III
What LoxaNova Does

We run the commercial engine.
You own the outcome.

LoxaNova is a self-contained domestic commercial organization built specifically for surgeon IP. We take a product from patent to operating room to acquisition-ready — and the surgeon retains ownership through every stage.

01
Innovate
Protect & Prepare

IP audit, maintenance management, 510(k) pathway mapping, and manufacturing sourcing. We handle the infrastructure that turns a patent into a market-ready product.

02
Prove
Build the Record

Proof-of-concept deployment in a controlled Texas market. Trained field educators in the OR. Every case documented. Every procedure tied to a patent family. Clean utilization data that supports a premium valuation.

03
Realize
Exit on Your Terms

Individual IP brokerage or full company acquisition. We bring the utilization data, the commercial track record, and the competitive tension that creates real negotiating leverage with strategic buyers.

§ IV
Operators

A team that has built
each piece of this before.

LoxaNova is not a venture experiment. The platform is being built by the person who pioneered the modern data stack in life sciences. The commercial organization is being built by the person who co-owned and operated one of the most successful orthopedic distribution territories in the country. And the entire thing is being led by an experienced multi-business operator who has run companies in parallel for two decades.

Michael Barrett
Platform Architecture
Michael's career has been a straight line from data infrastructure to commercial software for life sciences — at the firms that defined each of those categories in turn. He has built the kind of platform LoxaNova requires before, and he has watched what happens when life sciences companies do not own their own technology.
01
First Biotech CEO on Snowflake — 2017
Pioneered the modern data stack in life sciences
Michael was the CEO of the first biotech firm to implement Snowflake, back in 2017. Most of the life sciences industry is still relying on system integrators like ZS Associates and Accenture to retrofit AI and LLM capabilities onto legacy platforms, and the result is a locked-in chatbot or proprietary add-on that does not scale. Michael's stance has been the opposite from the start: use Snowflake as the foundation and follow its trajectory as a category-defining company. That position has proven correct.
02
Accenture — Data Management
Where the discipline started
Michael's earlier career was in Accenture's data management practice. The exposure to enterprise data programs across regulated industries is the foundation everything else is built on — and it is the reason Michael is candid about why pharma keeps getting locked into the same recurring consulting cycles.
03
Accolade — Where the IP-Ownership Philosophy Was Set
Patient services firm · Pennsylvania
At Accolade — a patient services firm using behavioral economics to influence how health plan members use their benefits — Michael took the explicit position that the company would build its own technology rather than lock into Salesforce or Microsoft Dynamics. The reasoning was straightforward: owning the software and harnessing the data was the differentiator, and it preserved acquisition optionality. That same philosophy applies directly to LoxaNova. We build it ourselves. We own the IP. That is what makes the eventual exit clean.
04
Veeva Systems — Head of Data Strategy & Data Science, US
The category leader in life sciences CRM
Veeva is the world leader in customer relationship management and other software for life sciences — including CRM for field sales and CRM for med tech. Michael led US data strategy and data science there and worked directly with the product owners and strategy leaders building those CRM tools. He knows what an effective life sciences engagement platform looks like from the inside, and he knows what a team has to do to build one.
05
Intarcia — Chief Data Officer & CIO
Implantable device · REMS training & human factors
At Intarcia, a Boston biotech, Michael was CDO and CIO during development of an osmotic mini-implantable pump (the ICA 650) that delivered a microdose of a GLP-1 to type 2 diabetics over a ninety-day period. Because it was a REMS product, Intarcia had to train and certify the clinical staff at endocrinologist offices and surgical centers on how to use the kit and place the device subcutaneously — scalpel, sutures, depth tool, the entire procedure. The training-and-certification problem Michael solved there is structurally identical to what LoxaNova has to solve for arthroscopic surgeons and OR staff using surgeon-developed devices. It is on the roadmap by design.
Jay Vaught
Commercial Organization
Fifteen years building medical device sales organizations that actually win. Jay's value is not a list of surgeon contacts — it is operational knowledge of how a commercial engine is built, compensated, trained, and run inside one of the most demanding categories in healthcare.
01
MEDINC of Texas — Co-Owner
Independent exclusive sales agency · Houston · Austin · San Antonio
Jay co-owned MEDINC of Texas, the independent exclusive sales agency that held Arthrex's commercial territories across Houston, Austin, and San Antonio — three of the most important orthopedic markets in the country. The MEDINC model — independent, exclusive, territory-owned, surgeon-facing, educational-first — is the same structural model LoxaNova is being built around. Not a venture experiment. A proven commercial architecture being extended into surgeon-owned IP.
02
The Reference Architecture
Full org structure across three Texas markets
At MEDINC, Jay built and operated a complete commercial org — from EVP down through Area VPs in each market, Directors of Medical Education and Operations, 17 territory Directors of Sales statewide, Area Specialists, Sales Reps, Sales Specialists, and Sales Associates. He understands rep compensation structures, physician training and OR support requirements, the operational infrastructure a sales org needs to succeed, where the pain points are, and where the opportunities are that most people never see.
03
The Consignment & Inventory Reality
How it actually works in the field
Jay has lived inside the consignment workflow that defines orthopedic device sales — kit ships to rep, hospital approval and check-in, OR case, devices used and logged, post-case reconciliation, returns, restocking. Hospital-specific quirks, GPO compliance, lot numbers, expiration tracking. The platform Michael is building is informed by the operator who has run all of it before.
Jason Lovelady
Operating Executive
Two decades operating multiple businesses in parallel. A sales career built in enterprise software and Texas dealership finance. The person who identified the LoxaNova opportunity, assembled the team around it, and is driving the commercial vision and investor relationships.
01
Built on Relationships
Construction · HVAC · technology · medical
Jason's career has been built on relationships as much as on execution. His network reaches across construction and HVAC, enterprise technology sales, and medical. LoxaNova was founded on the strength of a 30-plus year relationship network that spans industries, geographies, and disciplines. Jason's ability to identify aligned opportunities and bring the right people to the table is the connective tissue the organization runs on.
02
Four Active Companies — Run in Parallel
Multi-business operator · roofing · HVAC · consumer
Jason currently runs four active companies simultaneously: Carpenter's Roofing and Sheet Metal as President and Owner (21 years), Altec Roofing as President and Owner (11 years), AC America — the nationwide HVAC sales and financing platform — as Partner and operating principal, and Piper Laine Fit as operating principal. Two decades of running multiple organizations in parallel is the profile of a multi-business executive whose entire career has been spent building, scaling, and running real businesses across categories — not a thesis on paper.
03
Systemware — Regional Sales Manager
Document & content management software · enterprise mainframe
Before ownership, Jason was Regional Sales Manager at Systemware covering the Southwest, Midwest, and Southeast United States — selling document and content management software into mainframe enterprise systems. Territory ownership and enterprise sales discipline at scale: the foundation that builds an operator who understands exactly what a commercial engine has to do to generate revenue against complex, high-stakes buyers.
04
Frank Parra Autoplex
Irving, Texas · franchise operations
Jason began his management career as Finance Manager at Frank Parra Autoplex in Irving, Texas, and was promoted to General Sales Manager of the franchise. His leadership track record starts here.
05
SMU Cox · Texas Tech
Academic foundation
BBA from SMU Cox School of Business. Masters in Environmental Technology Management from Texas Tech University.
06
Board & Advisory Service
Current corporate, civic, and academic board positions
Currently serving on the SMU Dedman College Executive Board of Directors and the Corporate Board of Jupiter Medical Center. Additional executive board and advisory roles across civic, charitable, and business organizations in South Florida and Texas.
07
At LoxaNova
Strategy · capital · team assembly
Jason identified the LoxaNova opportunity, assembled the team around it, and is driving the commercial vision and investor relationships. He is extending two decades of operating leadership, sales discipline, and team building into the medical device IP commercialization space — alongside two domain experts who have built each piece of this before. The operating track record he brings is exactly what surgeon-owned IP has historically lacked.
§ V
Platform

Enterprise architecture
built on infrastructure that already exists.

LoxaNova is not a greenfield build. It is a focused commercial layer extended out of pharma-scale infrastructure that has been live, audited, and operating at scale for years.

§

Loxalytics operates at pharma scale — over a billion patient records on Snowflake Business Critical with HIPAA BAAs already in place, NVIDIA compute already provisioned, and life sciences commercial data models already built. LoxaNova extends that environment into orthopedic surgical device sales with a new field-facing engagement layer and an inventory module pharma does not need.

§ V.A · The Stack
Enterprise architecture, day one.

Six layers. Each one production-grade. Each one chosen so the platform itself is an owned asset, not a license that has to be ported during a transaction.

Layer Purpose Posture
Data Warehouse
Snowflake Business Critical — Loxalytics account 		Single source of truth. HCP data, territory structures, sales activity, inventory movements, OR case records, patent-linked product catalog, Sunshine Act reporting tables.
HIPAA BAA LiveEnterprise Grade
AI & Machine Learning
NVIDIA NIM on Spark · Snowflake Cortex · OpenAI API 		NVIDIA Spark handles local inference for anything touching sensitive data. Cortex runs ML directly on warehouse data without moving it. OpenAI handles non-sensitive tasks like coaching prompts, device recommendations, and insight generation.
PHI Never LeavesDifferentiator
Analytics & Dashboards
Streamlit in Snowflake · Sigma Computing 		Dashboards that run directly on warehouse data. Territory views, Sunshine Act compliance, inventory reconciliation, pipeline analytics, AI-generated forecasts — all native, no data movement.
NativeNo Data Movement
Engagement Layer · Current
Softr — no-code, connected to Snowflake 		A working healthcare-provider engagement tool that gets the team a clickable system fast. Accounts, contacts, territory performance, ASC and group-practice consignment activity, and surgeon onboarding — loaded with real Medicare and CMS data.
Validated Workflow
Engagement Layer · Owned Build
Node.js · React · React Native 		Once the workflow is validated in Softr, the platform pivots to frameworks that produce IP the entity owns outright. Same philosophy Michael set at Accolade: do not lock into Salesforce or Microsoft Dynamics. Build it. Own it.
Owned IPMobile + Web
Authentication
Auth0 — HIPAA BAA available 		Rep and manager login, territory-based role permissions, and enterprise SSO for hospital system integrations. SSO is a configuration change, not a rebuild.
HIPAA BAAEnterprise SSO
§ V.B · The Data Layer
The targeting infrastructure for surgeon-owned IP.
Surgeon Targeting · Live in the Snowflake Environment

Identify high-volume arthroscopic surgeons by CPT code — before a rep ever walks in the door.

Real Medicare and CMS claims data, loaded directly into the LoxaNova Snowflake environment and structured around arthroscopic procedure codes. The same surgeon-targeting layer a major med device company would use to position a new product line commercially.

That is not a sales tool. It is the difference between a commercial organization that knocks on doors and one that walks into the right office on the first visit.

Source
Medicare & CMS claims
Structure
Arthroscopic CPT codes
Output
Ranked surgeon list, by market
§ V.C · Where the Platform Is Heading
Stop asking reps to enter data.

Most CRMs and engagement tools, including the ones at Veeva, still ask territory managers and area VPs to hand-enter accounts, contacts, calls, and consignments. Next-best-action engines have been around for a while and do not solve the actual problem — rep time is the bottleneck, not recommendation quality. LoxaNova's engagement platform is being designed to flip that model entirely. The machine does the CRUD operations. The person has a better interface and a better way to do analytics.

i.
Natural Language CRUD
Agentic layer over the engagement platform
A rep on a phone or tablet says something like: "Create a new account for Mayo Clinic at 123 Main Street, add Dr. Michael Barrett as an orthopedic surgeon, Mayo is his primary place of surgery, add them into my territory." The agent listens, distills the prompt into a set of create / update / delete operations, and applies them to the engagement tool. No more clicking "add new account." No more searching menus. The rep talks, the system records.
ii.
Embedded Read-Only Q&A
Chatbot inside the engagement tool, answering from live data
"What HCP did I call on the most last month?" The rep stops searching through reports and views. The bot reads the data and answers. Embedded directly in the same engagement surface so the experience stays in one place.
iii.
Embedded Analytics via Snowflake Cortex
Natural language to analytics, no report-paging
The bulk of LoxaNova's data — sales, claims, Medicare, CMS, whatever else gets layered in — stays in Snowflake rather than being copied into the engagement layer. Snowflake Cortex is effectively a coding agent plus the ability to run natural language queries against a semantic layer that Snowflake lets us build without writing code. We expose Cortex as an agent inside the same React / Node framework, so the rep gets analytics in the same interface as the engagement workflow. "Show me my territory totals." "Who is the next doctor I should talk to." One mashup, one experience.
iv.
The Hex Analogy
Natural language to visualization, not reports
There is a company called Hex doing exceptional work on natural-language-to-visualization — you ask a question, you get an answer plus the chart that supports it, without ever opening a report. LoxaNova's engagement platform should be a small, med-device-shaped version of that idea. No more paging through Excel, Tableau, or Power BI to figure out how you are doing. You ask. The system answers contextually, and visualizes alongside.
§ V.D · Supply Chain & Inventory
Manufacturing is already running. Inventory is already in hand.

This is not a standing-start operation. The supply chain behind the foundational IP portfolio is active, the inventory is positioned for first commercial cases, and an international distribution relationship is already ordering product.

✓ Manufacturing — Confirmed and Running
Three Confirmed Sources
Injection molding: Shenzhen — described as very good, cheap, and fast. The molds are owned by the inventor and were built portable, so manufacturing can move to the US if strategy ever requires it.

Nitinol (nickel titanium memory metal): Sourced domestically in the US, 10 to 12 week lead time.

Elastomer: Manufactured domestically in the US. Significant supply purchased. Roadmap includes automation via a unique vertical molding machine.
✓ Inventory — In Hand
Ready for First Commercial Cases
Initial inventory received and broken down by SKU. The short cannula is the highest-volume SKU and is stocked accordingly.
1,000
Sterile — all lengths
2,500+
Non-sterile short
1,000
Non-sterile medium
400
Non-sterile long
✓ Insurance — Confirmed
$1M Facility Requirement
Current facility requirement is $1 million in liability insurance at primary Texas surgical centers — a manageable figure for first-stage operations. Entity structure and insurance procurement are routine pre-launch items, not blockers.
✓ International — Already Ordering
South Africa Distribution Active
A distributor in South Africa is already ordering product. Distribution had been throttled by supply constraints — now resolved by the current inventory position. This is an existing commercial relationship, not a prospect. International demand exists without any active selling effort.
§ V.E · Platform Roadmap
Training and certifying the people in the OR.

The next major addition to the platform roadmap is medical education and rep certification — and it is informed by direct experience, not a feature wishlist.

i · Reference Lesson
The Intarcia REMS Template
At Intarcia, the ICA 650 implantable pump was a REMS product. Michael's team had to train and certify the clinicians at endocrinologist offices and surgical centers on how to use the kit — scalpel, sutures, the placement tool that set the pump at the correct subcutaneous depth — and attest that they had completed the certified procedure. Structurally identical to what surgeon-developed devices will need in the OR for arthroscopic procedures.
ii · Reference Architecture
Acto — LLM & Avatar Training
A company called Acto is delivering approved, medically and legally reviewed materials conversationally — reps interact with an avatar instead of paging through hundred-page PowerPoints, ISI documents, and FDA labels. The result is faster ramp, current information, and an audit trail of who has consumed which approved content. A strong reference model for how LoxaNova handles rep enablement, change management, and onboarding as the org scales.
iii · Long-Arc Capability
OR Staff Certification
The training problem in med tech is broader than the sales team. The surgical team using a surgeon-developed device needs documented training and proof of certification on the procedure itself. Building that capability into the LoxaNova platform — scalable, auditable, tied to the device and to the case — is the long-arc addition to the roadmap that ties directly back to the REMS work Michael did at Intarcia.
§ VI
Suremka LLC — The Foundation

Thirteen patents.
One focused thesis.

Every arthroscopic procedure uses a cannula. The Suremka portfolio owns a meaningful piece of that space — surgical access and instrumentation technology developed over a decade of high-volume clinical practice. The portfolio is clean. No existing licenses. No encumbrances. Ready to move.

9
Issued US patents covering surgical access and instrumentation
1
European patent active in UK, France, and Germany
4
Pending applications including newest filed June 2025
Patent Description Year Status
8,777,902Retractable Cannula — Generation 12014Issued
10,258,368Retractable Cannula — Generation 22019Issued
EP15806528.4Retractable Cannula — UK, France, Germany2020European
10,342,577Surgical Devices and Methods2019Issued
10,687,846Surgical Devices and Methods — Divisional2020Issued
11,607,246Surgical Device Deployment Apparatuses2023Issued
11,607,322Graft Compression System2023Issued
12,427,039Graft Compression System — CIP2025Issued
11,627,985Surgical Devices & Deployment Apparatuses2023Issued
18/355,936Surgical Devices & Deployment ApparatusesPendingPending
18/336,287Knotless Suture Shuttling & Anchoring SystemPendingPending
18/295,414Surgical Devices & Deployment ApparatusesPendingPending
19/252,607Surgical Devices & Deployment Apparatuses — Newest2025Pending
§ VII
What This Means For You

Mailbox money.
On your terms.

The goal is simple. You focus on patients. LoxaNova runs the commercial organization, builds the data record, and creates the conditions for a premium outcome. The surgeon entrepreneur finally has a partner who knows how to execute.

I.
No Operational Burden

You don't manage reps, chase purchase orders, or sit in VAT committee meetings. LoxaNova handles the entire commercial layer. Your time stays in the OR.

II.
Real Utilization Data

Every case documented. Every procedure tied to your IP. When a strategic buyer asks for proof of market adoption, we hand them a clean report instead of a pitch deck.

III.
Negotiating Leverage

A proven commercial track record changes the acquisition conversation. You stop being a seller with an idea and become a seller with a business. That distinction is worth multiples.

IV.
A Bigger Vision

This is the first chapter. LoxaNova becomes the platform other surgeon entrepreneurs use to bring their IP to market. Your success builds something that helps the entire community of surgical innovators.

§ VIII
May 12, 2026 · Dallas

This is the conversation
worth having.

No term sheets today. No legal discussions. Just three people who have built real things in this industry sitting down to talk about whether this is worth doing together. We believe it is.

LoxaNova · Innovate · Prove · Realize